All stock lists
Unlock the score
Anixa Biosciences Inc (NASDAQ:ANIX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
2.94-0.05 (-1.71%)
Insider Score
/ 100
ANIX Insider Score
Anixa Biosciences Inc has a live Insider Score.
Scored on 9 qualifying trades from 4 insiders in the last 90 days.
Financial Health Score
Fair
From ANIX’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars
Profitability—
No revenue reported, so there is no margin to score.
- Revenue
- $0
- Net income
- -$10.4M
- Net margin
- —
Leverage20 / 20
Little or no net debt.
- Total debt
- $174K
- Cash
- $1.4M
- Debt / equity
- 0.01
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $14.9M
- Current liabilities
- $1.7M
- Current ratio
- 8.54
Cash generation3 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$7.4M
- Free cash flow
- -$7.4M
Dilution & runway0 / 20
Burning cash with under a year of runway — expect a raise.
- Shares outstanding
- 34.2M
- Share growth (1y)
- 5.3%
- Cash runway
- 2 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
ANIX Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jul 31, 2026 | Apr 30, 2026 | Jan 31, 2026 | Oct 31, 2025 | Jul 31, 2025 | Apr 30, 2025 |
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — | — | — | — |
| Cost of Revenue | 10.00 K | 0.00 | 0.00 | 9.00 K | 0.00 | 0.00 |
| Gross Profit | -10.00 K | 0.00 | 0.00 | -9.00 K | 0.00 | 0.00 |
| SG&A Expense | 1.41 M | 1.39 M | 1.61 M | 1.73 M | 1.38 M | 1.68 M |
| R&D Expense | 1.33 M | 1.26 M | 1.10 M | 1.14 M | 1.05 M | 1.32 M |
| Operating Expenses | 2.74 M | 2.65 M | 2.72 M | 2.87 M | 2.44 M | 3.00 M |
| Operating Income | -2.74 M | -2.65 M | -2.72 M | -2.88 M | -2.44 M | -3.00 M |
| Pretax Income | -2.63 M | -2.54 M | -2.58 M | -2.72 M | -2.28 M | -2.81 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -2.61 M | -2.56 M | -2.56 M | -2.69 M | -2.26 M | -2.79 M |
| EPS (Basic) | -0.08 | -0.07 | -0.08 | -0.08 | -0.07 | -0.09 |
| EPS (Diluted) | -0.08 | -0.07 | -0.08 | -0.08 | -0.07 | -0.09 |
| Shares Outstanding | 34.18 M | 33.59 M | 33.24 M | 32.45 M | 32.48 M | 32.20 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.